AR049292A1 - Metodo para tratar lupus con un anticuerpo cd20 - Google Patents
Metodo para tratar lupus con un anticuerpo cd20Info
- Publication number
- AR049292A1 AR049292A1 ARP050102269A ARP050102269A AR049292A1 AR 049292 A1 AR049292 A1 AR 049292A1 AR P050102269 A ARP050102269 A AR P050102269A AR P050102269 A ARP050102269 A AR P050102269A AR 049292 A1 AR049292 A1 AR 049292A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- exposure
- medicament
- subject
- agent
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 7
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 title abstract 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 title abstract 4
- 206010025135 lupus erythematosus Diseases 0.000 title abstract 3
- 229940127089 cytotoxic agent Drugs 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 4
- 229940123038 Integrin antagonist Drugs 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 239000000430 cytokine receptor antagonist Substances 0.000 abstract 2
- 239000002254 cytotoxic agent Substances 0.000 abstract 2
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 2
- 239000005556 hormone Substances 0.000 abstract 2
- 229940088597 hormone Drugs 0.000 abstract 2
- 229940125721 immunosuppressive agent Drugs 0.000 abstract 2
- 239000003018 immunosuppressive agent Substances 0.000 abstract 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 abstract 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 abstract 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 abstract 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 abstract 1
- 229960002170 azathioprine Drugs 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 229960004397 cyclophosphamide Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229960001428 mercaptopurine Drugs 0.000 abstract 1
- 229960000485 methotrexate Drugs 0.000 abstract 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 abstract 1
- 229960004866 mycophenolate mofetil Drugs 0.000 abstract 1
- 229960004641 rituximab Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
La presente trata de un método para tratar lupus con un anticuerpo CD20 y un artículo de manufactura para el mismo. Reivindicacion 1: Un método para el tratamiento de lupus en un sujeto que comprende administrar una cantidad eficaz de un anticuerpo CD20 al sujeto para proveer una exposicion inicial al anticuerpo de aproximadamente 0,5 a 4 gramos seguido de una segunda exposicion al anticuerpo de aproximadamente 0,5 a 4 gramos, donde la segunda exposicion no se provee hasta desde aproximadamente 16 a 54 semanas desde la exposicion inicial y cada una de las exposiciones a anticuerpo se provee al sujeto como una dosis unica o como dos o tres dosis separadas de anticuerpo. Reivindicacion 12: El método de cualquiera de las reivindicaciones 1-11, donde se administra un segundo medicamento en una cantidad eficaz con una exposicion al anticuerpo donde el anticuerpo CD20 es un primer medicamento. Reivindicacion 14: El método de la reivindicacion 12 o 13, donde el segundo medicamento es un agente quimioterapéutico, un agente inmunosupresor, un agente citotoxico, un antagonista de integrina, un antagonista de citoquina o una hormona. Reivindicacion 15: El método de la reivindicacion 14, donde se administra un corticoesteroide, metotrexato, ciclofosfamida, azatioprina, micofenolato mofetil o 6-mercaptopurina. Reivindicacion 21: El método de cualquiera de las reivindicaciones 1-20, donde el anticuerpo es rituximab o un 2H7 humanizado que comprende la secuencia de dominio variable en las SEC ID NOS: 2 y 8 o un anticuerpo que comprende las secuencias de dominio variable en las SEC ID NOS: 18 y 19. Reivindicacion 25: El artículo de la reivindicacion 24, donde el segundo medicamento es un agente quimioterapéutico, un agente inmunosupresor, un agente citotoxico, un antagonista de integrina, un antagonista de citoquina o una hormona.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57723504P | 2004-06-04 | 2004-06-04 | |
| US61799704P | 2004-10-11 | 2004-10-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049292A1 true AR049292A1 (es) | 2006-07-12 |
Family
ID=35503635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102269A AR049292A1 (es) | 2004-06-04 | 2005-06-02 | Metodo para tratar lupus con un anticuerpo cd20 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20060024295A1 (es) |
| EP (1) | EP1765400A2 (es) |
| JP (1) | JP2008501706A (es) |
| AR (1) | AR049292A1 (es) |
| AU (1) | AU2005251764A1 (es) |
| BR (1) | BRPI0510885A (es) |
| CA (1) | CA2568336A1 (es) |
| DO (1) | DOP2005000108A (es) |
| IL (1) | IL179325A0 (es) |
| MX (1) | MXPA06014067A (es) |
| PA (1) | PA8635501A1 (es) |
| PE (1) | PE20060688A1 (es) |
| RU (1) | RU2396980C2 (es) |
| SV (1) | SV2006002131A (es) |
| TW (1) | TW200608994A (es) |
| WO (1) | WO2005120437A2 (es) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2904259C (en) * | 1999-05-07 | 2016-11-15 | Genentech, Inc. | Use of rituximab to treat vasculitis |
| MXPA03002262A (es) * | 2000-09-18 | 2003-10-15 | Idec Pharma Corp | Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b. |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| DK2380910T3 (en) | 2003-11-05 | 2015-10-19 | Roche Glycart Ag | Antigen binding molecules with increased Fc receptor binding affinity and effector function |
| RU2007130688A (ru) * | 2005-01-13 | 2009-02-20 | Дженентек, Инк. (Us) | Способ лечения |
| WO2006089095A2 (en) | 2005-02-17 | 2006-08-24 | Biogen Idec Ma Inc. | Treating neurological disorders |
| RS51845B (sr) | 2005-04-22 | 2012-02-29 | Eli Lilly And Company | Specifična tgf beta 1 antitela |
| WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
| US10307481B2 (en) | 2005-07-25 | 2019-06-04 | Aptevo Research And Development Llc | CD37 immunotherapeutics and uses thereof |
| US20080279848A1 (en) * | 2006-03-16 | 2008-11-13 | Genentech, Inc. | Methods of treating lupus using CD4 antibodies |
| AU2007227609A1 (en) * | 2006-03-16 | 2007-09-27 | Genentech, Inc. | Methods of treating lupus using CD4 antibodies |
| JP2009543579A (ja) | 2006-07-19 | 2009-12-10 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | 抗炎症反応のための標的としてのＷＳＸ−１／ｐ２８ |
| KR101561020B1 (ko) | 2007-07-31 | 2015-10-26 | 리제너론 파아마슈티컬스, 인크. | 사람 ｃｄ20에 대한 사람 항체 및 이의 사용 방법 |
| DE102007057513B4 (de) | 2007-11-29 | 2016-08-04 | BSH Hausgeräte GmbH | Haushaltsgerät, insbesondere Geschirrspülmaschine |
| NZ603059A (en) | 2008-04-11 | 2014-07-25 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| US20100021460A1 (en) * | 2008-07-15 | 2010-01-28 | Genentech, Inc. | Methods of Treating Autoimmune Diseases Using CD4 Antibodies |
| AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| EP2435476A4 (en) * | 2009-05-27 | 2013-04-17 | Synageva Biopharma Corp | ANTIBODIES OBTAINED FROM BIRDS |
| RU2539112C2 (ru) * | 2009-09-03 | 2015-01-10 | Дженентек, Инк. | Способы лечения, диагностики и мониторинга ревматоидного артрита |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| KR20130009760A (ko) | 2010-02-10 | 2013-01-23 | 이뮤노젠 아이엔씨 | Ｃｄ２０ 항체 및 이의 용도 |
| WO2011143408A1 (en) * | 2010-05-13 | 2011-11-17 | Genentech, Inc. | Use of neuropilin-1 antagonists for the treatment of cancer |
| JP6271254B2 (ja) | 2011-02-28 | 2018-01-31 | ジェネンテック， インコーポレイテッド | Ｂ細胞アンタゴニストに対する生物学的マーカー及び応答を予測するための方法 |
| ES2732213T3 (es) | 2011-05-21 | 2019-11-21 | Macrogenics Inc | Moléculas que se unen a CD3 capaces de unirse a CD3 humano y no humano |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| WO2015051234A2 (en) * | 2013-10-04 | 2015-04-09 | Biogen Idec Ma Inc. | Tweak antagonists for treating lupus nephritis and muscle atrophy |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| ES2809455T3 (es) | 2014-11-17 | 2021-03-04 | Regeneron Pharma | Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20 |
| AR104368A1 (es) | 2015-04-03 | 2017-07-19 | Lilly Co Eli | Anticuerpos biespecíficos anti-cd20- / anti-baff |
| EP3294771A1 (en) * | 2015-05-11 | 2018-03-21 | H. Hoffnabb-La Roche Ag | Compositions and methods of treating lupus nephritis |
| EP3303295A2 (fr) | 2015-06-05 | 2018-04-11 | Inoviem Scientific | Analogues de l'hydroxychloroquine (hcq) depourvus de toxicite retinienne |
| AU2016361462B2 (en) | 2015-11-27 | 2023-09-21 | Csl Limited | CD131 binding proteins and uses thereof |
| HRP20250234T1 (hr) | 2018-08-31 | 2025-04-11 | Regeneron Pharmaceuticals, Inc. | Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitijela |
| CN109406775A (zh) * | 2018-10-12 | 2019-03-01 | 东莞市暨科生物科技有限公司 | 自身免疫性疾病患者免疫功能评估试剂盒及评估方法 |
| WO2021050645A1 (en) * | 2019-09-12 | 2021-03-18 | Genentech, Inc. | Compositions and methods of treating lupus nephritis |
| US12234291B2 (en) | 2020-08-05 | 2025-02-25 | Synthekine, Inc. | IL2RB binding molecules and methods of use |
| EP4192862A4 (en) | 2020-08-05 | 2025-01-08 | Synthekine, Inc. | Gp130 binding molecules and methods of use |
| WO2022032042A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il12 receptor synthetic cytokines and methods of use |
| KR20230061393A (ko) | 2020-08-05 | 2023-05-08 | 신테카인, 인크. | IL10Rb 결합 분자 및 사용 방법 |
| WO2022031929A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il12rb1-binding molecules and methods of use |
| CN117242088A (zh) | 2020-08-05 | 2023-12-15 | 辛德凯因股份有限公司 | Il10受体结合分子和使用方法 |
| CN116723859A (zh) | 2020-08-05 | 2023-09-08 | 辛德凯因股份有限公司 | IL27Rα结合分子及使用方法 |
| EP4192863A4 (en) | 2020-08-05 | 2025-07-30 | Synthekine Inc | IL2RG BINDING MOLECULES AND METHODS OF USE |
| JP7767391B2 (ja) | 2020-08-05 | 2025-11-11 | シンセカイン インコーポレイテッド | ＩＬ１０Ｒａ結合分子および使用方法 |
| WO2022032045A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | IL10Rα/IL2Rγ SYNTHETIC CYTOKINES |
| US12018085B2 (en) | 2020-08-05 | 2024-06-25 | Synthekine, Inc. | Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases |
| EP4192490A4 (en) | 2020-08-05 | 2025-01-01 | Synthekine, Inc. | IL27RA-BINDING MOLECULES AND METHODS OF USE |
| WO2022032023A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il23r binding molecules and methods of use |
| US12122839B2 (en) | 2020-08-05 | 2024-10-22 | Synthekine, Inc. | IFNGR binding synthetic cytokines and methods of use |
| CA3204162A1 (en) * | 2021-01-11 | 2022-07-14 | Robert Kastelein | Compositions and methods related to receptor pairing |
| IL312692A (en) | 2021-11-16 | 2024-07-01 | Genentech Inc | Methods and compositions for the treatment of systemic lupus erythematosus (SLE) with musontuzumab |
| WO2025054537A1 (en) * | 2023-09-08 | 2025-03-13 | Fate Therapeutics, Inc. | Ipsc-derived effector cells for autoimmune disease treatment |
| US20250197501A1 (en) * | 2023-12-19 | 2025-06-19 | Development Center For Biotechnology | Recombinant antibody, immunoconjugate comprising the same, and uses thereof in treating cancers |
| WO2025255012A1 (en) * | 2024-06-03 | 2025-12-11 | Uct Bioscience Co., Ltd. | Anti-grp78 antibody, immunoconjugate and uses thereof |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4690905A (en) * | 1983-11-16 | 1987-09-01 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method for removal of human antibodies to native DNA from serum |
| US6893625B1 (en) * | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5506126A (en) * | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
| US4861579A (en) * | 1988-03-17 | 1989-08-29 | American Cyanamid Company | Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies |
| SU1697817A1 (ru) * | 1988-07-07 | 1991-12-15 | Минский государственный медицинский институт | Способ лечени системной красной волчанки |
| IE922437A1 (en) * | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| US6136310A (en) * | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| ES2136092T3 (es) * | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5573905A (en) * | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| ATE139900T1 (de) * | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US7744877B2 (en) * | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
| US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| ATE306930T1 (de) * | 1994-08-12 | 2005-11-15 | Immunomedics Inc | Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper |
| US20010056066A1 (en) * | 1996-07-26 | 2001-12-27 | Smithkline Beecham Corporation | Method of treating immune cell mediated systemic diseases |
| AU5605398A (en) * | 1996-12-11 | 1998-07-03 | University Of Florida | Novel methods and compositions for treatment of autoimmune diseases |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| AU8296098A (en) * | 1997-07-08 | 1999-02-08 | Board Of Regents, The University Of Texas System | Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
| US6242195B1 (en) * | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6528624B1 (en) * | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| EP1946775A3 (en) * | 1998-08-11 | 2008-08-06 | Biogen Idec Inc. | Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody |
| US6224866B1 (en) * | 1998-10-07 | 2001-05-01 | Biocrystal Ltd. | Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors |
| DK1131096T3 (da) * | 1998-11-09 | 2010-05-17 | Biogen Idec Inc | Anti-CD20-antistofbehandling af patienter, der modtager knoglemarvs- eller periferisk blodstamcelletransplantationer |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6383276B1 (en) * | 1999-03-12 | 2002-05-07 | Fuji Photo Film Co., Ltd. | Azomethine compound and oily magenta ink |
| ES2601882T5 (es) * | 1999-04-09 | 2021-06-07 | Kyowa Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| CA2904259C (en) * | 1999-05-07 | 2016-11-15 | Genentech, Inc. | Use of rituximab to treat vasculitis |
| JP4286483B2 (ja) * | 1999-06-09 | 2009-07-01 | イムノメディクス， インコーポレイテッド | Ｂ細胞をターゲットとする抗体を使用する自己免疫疾患に対する免疫療法 |
| DE19930748C2 (de) * | 1999-07-02 | 2001-05-17 | Infineon Technologies Ag | Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip |
| AU6929100A (en) * | 1999-08-23 | 2001-03-19 | Biocrystal Limited | Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis |
| US20020006404A1 (en) * | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| IL149500A0 (en) * | 1999-11-08 | 2002-11-10 | Idec Pharma Corp | Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy |
| US6368061B1 (en) * | 1999-11-30 | 2002-04-09 | Siemens Automotive, Inc. | High efficiency and low weight axial flow fan |
| US20030185796A1 (en) * | 2000-03-24 | 2003-10-02 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma |
| EP1267927A1 (en) * | 2000-03-24 | 2003-01-02 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2 |
| EP1283722A1 (en) * | 2000-03-31 | 2003-02-19 | Idec Pharmaceuticals Corporation | Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma |
| DK2857516T3 (en) * | 2000-04-11 | 2017-08-07 | Genentech Inc | Multivalent antibodies and uses thereof |
| EP1286692A4 (en) * | 2000-04-25 | 2004-11-17 | Idec Pharma Corp | INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR THE TREATMENT OF LYMPHOMAS OF THE CENTRAL NERVOUS SYSTEM |
| SI1296714T1 (sl) * | 2000-06-22 | 2010-01-29 | S For Entpr University Of Iowa | Kombinacija CpG-ja in protiteles, usmerjenih proti CD19, CD20, CD22 ali CD40 za zdravljenje ali preprečevanje raka |
| EP1288205B1 (en) * | 2000-08-18 | 2011-02-02 | Ajinomoto Co., Inc. | Novel phenylalanine derivatives |
| WO2002016414A2 (en) * | 2000-08-22 | 2002-02-28 | Micromet Ag | Composition for the elimination of autoreactive b-cells |
| MXPA03002262A (es) * | 2000-09-18 | 2003-10-15 | Idec Pharma Corp | Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b. |
| AU2002256971B2 (en) * | 2000-12-28 | 2008-04-03 | Altus Pharmaceuticals Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
| US20030103971A1 (en) * | 2001-11-09 | 2003-06-05 | Kandasamy Hariharan | Immunoregulatory antibodies and uses thereof |
| ES2364816T3 (es) * | 2001-04-02 | 2011-09-14 | Genentech, Inc. | Terapia de combinación. |
| US7718387B2 (en) * | 2001-09-20 | 2010-05-18 | Board Of Regents, The University Of Texas System | Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays |
| HUP0600342A3 (en) * | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| EP1454898A4 (en) * | 2001-12-13 | 2006-12-13 | Ajinomoto Kk | NEW PHENYL ALANIDE DERIVATIVES |
| US20040093621A1 (en) * | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| AU2003208415B2 (en) * | 2002-02-14 | 2009-05-28 | Immunomedics, Inc. | Anti-CD20 antibodies and fusion proteins thereof and methods of use |
| US20030180292A1 (en) * | 2002-03-14 | 2003-09-25 | Idec Pharmaceuticals | Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy |
| WO2003085119A1 (en) * | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa |
| US20030219818A1 (en) * | 2002-05-10 | 2003-11-27 | Bohen Sean P. | Methods and compositions for determining neoplastic disease responsiveness to antibody therapy |
| DK2289936T3 (en) * | 2002-12-16 | 2017-07-31 | Genentech Inc | IMMUNGLOBULIN VARIATIONS AND APPLICATIONS THEREOF |
| RU2358762C9 (ru) * | 2003-04-09 | 2016-10-10 | Джинентех, Инк. | Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа |
| AR044388A1 (es) * | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| RU2370775C2 (ru) * | 2003-07-29 | 2009-10-20 | Дженентек, Инк. | Анализ нейтрализующих антител и его применение |
| US8147832B2 (en) * | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
| BRPI0412629A (pt) * | 2003-08-29 | 2006-09-26 | Genentech Inc | método de tratamento de disfunção ocular em mamìferos |
-
2005
- 2005-06-02 US US11/143,077 patent/US20060024295A1/en not_active Abandoned
- 2005-06-02 MX MXPA06014067A patent/MXPA06014067A/es not_active Application Discontinuation
- 2005-06-02 RU RU2006146927/14A patent/RU2396980C2/ru not_active IP Right Cessation
- 2005-06-02 TW TW094118187A patent/TW200608994A/zh unknown
- 2005-06-02 AU AU2005251764A patent/AU2005251764A1/en not_active Abandoned
- 2005-06-02 SV SV2005002131A patent/SV2006002131A/es unknown
- 2005-06-02 AR ARP050102269A patent/AR049292A1/es not_active Application Discontinuation
- 2005-06-02 CA CA002568336A patent/CA2568336A1/en not_active Abandoned
- 2005-06-02 DO DO2005000108A patent/DOP2005000108A/es unknown
- 2005-06-02 BR BRPI0510885-3A patent/BRPI0510885A/pt not_active IP Right Cessation
- 2005-06-02 WO PCT/US2005/019550 patent/WO2005120437A2/en not_active Ceased
- 2005-06-02 EP EP05786559A patent/EP1765400A2/en not_active Withdrawn
- 2005-06-02 JP JP2007515612A patent/JP2008501706A/ja active Pending
- 2005-06-02 PA PA20058635501A patent/PA8635501A1/es unknown
- 2005-08-17 PE PE2005000625A patent/PE20060688A1/es not_active Application Discontinuation
-
2006
- 2006-09-28 US US11/536,580 patent/US20070025988A1/en not_active Abandoned
- 2006-11-16 IL IL179325A patent/IL179325A0/en unknown
-
2010
- 2010-07-23 US US12/842,529 patent/US20100303810A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008501706A (ja) | 2008-01-24 |
| TW200608994A (en) | 2006-03-16 |
| AU2005251764A1 (en) | 2005-12-22 |
| CA2568336A1 (en) | 2005-12-22 |
| MXPA06014067A (es) | 2007-02-15 |
| PA8635501A1 (es) | 2006-06-02 |
| RU2006146927A (ru) | 2008-08-10 |
| US20100303810A1 (en) | 2010-12-02 |
| RU2396980C2 (ru) | 2010-08-20 |
| SV2006002131A (es) | 2006-01-26 |
| PE20060688A1 (es) | 2006-09-23 |
| BRPI0510885A (pt) | 2007-12-26 |
| WO2005120437A2 (en) | 2005-12-22 |
| IL179325A0 (en) | 2007-03-08 |
| EP1765400A2 (en) | 2007-03-28 |
| US20070025988A1 (en) | 2007-02-01 |
| WO2005120437A3 (en) | 2006-06-29 |
| DOP2005000108A (es) | 2007-06-15 |
| US20060024295A1 (en) | 2006-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR049292A1 (es) | Metodo para tratar lupus con un anticuerpo cd20 | |
| AR049200A1 (es) | Metodo para tratar esclerosis multiple con una composicion que contiene un anticuerpo cd20 | |
| Cang et al. | Novel CD20 monoclonal antibodies for lymphoma therapy | |
| US20180071293A1 (en) | Tec family kinase inhibitor adjuvant therapy | |
| PE20211915A1 (es) | Receptores de antigenos quimericos dirigidos al antigeno de maduracion de celulas b y sus metodos de uso | |
| CL2008003788A1 (es) | Composicion farmaceutico que comprende a) el anticuerpo b-ly1 humanizado (anti-cd20/antigeno de referenciacion restringida del linfocito b humano/bp35, de tipo ii), b) opcionalmente de 0,001% al 1%p/v de por lo menos un surfactante, y c) de 1 a 100 mm de un tampon; uso para tratar enfermedades relacionadas con cd20. | |
| AR052219A1 (es) | Metodo para tratar la vasculitis | |
| JP2008530142A5 (es) | ||
| JP2019529388A5 (es) | ||
| JP2017528462A5 (es) | ||
| TN2015000452A1 (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas | |
| AR050418A1 (es) | Dosificacion fija de anticuerpos her | |
| JP2016512835A5 (es) | ||
| DOP2006000013A (es) | Dosis de anticuerpos en el tratamiento de enfermedades asociadas a las celulas b | |
| AR048502A1 (es) | Sinergia terapeutica de compuestos anti-cancer | |
| CN110769837A (zh) | 与五氮杂大环状环配合物的联合癌症免疫疗法 | |
| AR047988A1 (es) | Combinaciones antineoplásicas de cci-779 y rituximab | |
| RS63238B1 (sr) | Kombinovana terapija sa anti-cd19 antitelom i azotnim senfom | |
| US20200376148A1 (en) | Combination cancer immunotherapy with pentaaza macrocyclic ring complex | |
| JP2015172060A5 (es) | ||
| FI3630177T3 (fi) | Hoitoparadigma anti-cd19-vasta-aineen ja venetoklaksin yhdistelmähoidolle | |
| CA3181827A1 (en) | Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirp?-cd47 innate immune checkpoint | |
| JP2018506533A5 (es) | ||
| JP2018150292A (ja) | がん治療 | |
| AR049136A1 (es) | Composicion y metodo con irinotecan (cpt-11) y un inhibidor del egfr,como erlotinib |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |